<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01212406</url>
  </required_header>
  <id_info>
    <org_study_id>VIT001</org_study_id>
    <nct_id>NCT01212406</nct_id>
  </id_info>
  <brief_title>Vitamin D in Bronchiolitis Obliterans Syndrome</brief_title>
  <acronym>VIT001</acronym>
  <official_title>A Randomized Double Blind Placebo Controlled Trial With Vitamin D to Prevent Bronchiolitis Obliterans Syndrome After Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D deficiency occurs in around 50% of our transplant population. Preventive treatment
      with Vitamin D (D-cure) can reduce the prevalence of Bronchiolitis Obliterans Syndrome after
      lung transplantation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Prospective, interventional, randomized, double-blind, placebo-controlled trial.

        -  Clinical setting (tertiary University Hospital).

        -  Investigator-driven, no pharmaceutical sponsor.

        -  Lung transplant recipients.

        -  Add-on of study-drug (placebo or vitamin D) to 'standard of care' (standardized, routine
           immunosuppressive and infectious prophylactic protocol).

        -  1:1 inclusion ratio (placebo:Vitamin D).

        -  Randomisation at discharge after informed consent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Bronchiolitis Obliterans syndrome (BOS) (grade 1) at 2 years after transplantation</measure>
    <time_frame>2 years after transplantation</time_frame>
    <description>BOS= decline in forced expiratory volume in 1 second (FEV1) with at least 80% compared to the best post-operative value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of BOS (grade 1) at 3 years after transplantation</measure>
    <time_frame>3 years after transplantation</time_frame>
    <description>her-evaluation of data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bronchoalveolar lavage</measure>
    <time_frame>during 2 and 3y of follow-up</time_frame>
    <description>cellularity, protein and mRNA concentration and microbiology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood</measure>
    <time_frame>During 2 and 3 years of follow-up</time_frame>
    <description>Protein and mRNA concentration, cellularity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rejection rates</measure>
    <time_frame>During 2 and 3 years of follow-up</time_frame>
    <description>Acute rejection and lymphocytic bronchiolitis rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reflux</measure>
    <time_frame>During 2 and 3 years of follow-up</time_frame>
    <description>clinical and biochemical approach</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection rates</measure>
    <time_frame>During 2 and 3 years of follow-up</time_frame>
    <description>cytomegalovirus (CMV) and non- CMV infection rates</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Allograft Rejection</condition>
  <condition>Lung Transplantation</condition>
  <condition>Bronchiolitis Obliterans</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olive oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Addition of D-cure (100.000U) to standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>D-Cure</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable LTx recipients at discharge after transplantation.

          -  Signed informed consent

          -  Adult (age at least 18 years old at moment of transplantation)

          -  Able to take oral medication

        Exclusion Criteria:

          -  Prolonged and/or complicated Intensive care unit-course after transplantation.

          -  Early (&lt;30 days post-transplant) post-operative death

          -  Major suture problems (airway stenosis or stent)

          -  Retransplantation (lung)

          -  Previous transplantation (solid organ)

          -  Multi-organ transplantation (lung+ other solid organ)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geert M Verleden, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ gasthuisberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Ramirez AM, Wongtrakool C, Welch T, Steinmeyer A, Zügel U, Roman J. Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells. J Steroid Biochem Mol Biol. 2010 Feb 15;118(3):142-50. doi: 10.1016/j.jsbmb.2009.11.004. Epub 2009 Nov 17.</citation>
    <PMID>19931390</PMID>
  </reference>
  <reference>
    <citation>Zittermann A, Schleithoff SS, Götting C, Fuchs U, Kuhn J, Kleesiek K, Tenderich G, Koerfer R. Calcitriol deficiency and 1-year mortality in cardiac transplant recipients. Transplantation. 2009 Jan 15;87(1):118-24. doi: 10.1097/TP.0b013e31818c2708.</citation>
    <PMID>19136901</PMID>
  </reference>
  <reference>
    <citation>Janssens W, Bouillon R, Claes B, Carremans C, Lehouck A, Buysschaert I, Coolen J, Mathieu C, Decramer M, Lambrechts D. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax. 2010 Mar;65(3):215-20. doi: 10.1136/thx.2009.120659. Epub 2009 Dec 8.</citation>
    <PMID>19996341</PMID>
  </reference>
  <reference>
    <citation>Vanaudenaerde BM, Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, Van Raemdonck DE, Dupont LJ, Verleden GM. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J. 2008 Oct;32(4):832-43. doi: 10.1183/09031936.00134307. Review.</citation>
    <PMID>18827151</PMID>
  </reference>
  <reference>
    <citation>Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GB, Snell GI, Yousem S. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002 Mar;21(3):297-310. Review.</citation>
    <PMID>11897517</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>November 10, 2015</last_update_submitted>
  <last_update_submitted_qc>November 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Organ rejection</keyword>
  <keyword>Lung transplantation</keyword>
  <keyword>Bronchiolitis Obliterans</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiolitis</mesh_term>
    <mesh_term>Bronchiolitis Obliterans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

